The 19th International Myeloma Society (IMS) Annual Meeting was held in Los Angeles, California, from August 25-27. This meeting brought together leading experts in the field of multiple myeloma to discuss and present preclinical and clinical data, as well as novel approaches in the treatment and diagnosis of myeloma.
View all videos

IMS 2022

The 19th International Myeloma Society Annual Meeting
25–27 August 2022 | Los Angeles, California
VJHemOncVJHemOnc@VJHemOnc·
3h

We spoke to @adamssperling (@DanaFarber), who shared some insights into the role of clonal hematopoiesis in multiple myeloma and other hematological malignancies:

🎥: http://ow.ly/GGiK50KVRjM

#MMsm #HemOnc #BloodCancerAwarenessMonth #IMS2022

Reply on Twitter 1575727491070808071Retweet on Twitter 15757274910708080711Like on Twitter 15757274910708080714View Tweet 1575727491070808071
VJHemOncVJHemOnc@VJHemOnc·
12h

We had a great interview with Catherine Coombs of @UNC, who shared some insights into novel BTK inhibitors in CLL and future outlooks.

@SocietyofHemOnc #SOHO22 #HemOnc #LeuSM #CLLsm

Reply on Twitter 1575595071273021442Retweet on Twitter 15755950712730214421Like on Twitter 15755950712730214423View Tweet 1575595071273021442
VJHemOncVJHemOnc@VJHemOnc·
12h

#SOHO22 | Peter Valk (@ErasmusMC) discusses TP53-mutated AML and MDS, the prognostic value of FLT3-ITD residual disease in AML, and more.

Visit http://VJHemOnc.com for our interviews from this year's meeting!

#SOHO2022 #HemOnc #LeuSM #AMLsm #MDSsm

Reply on Twitter 1575591500834295808Retweet on Twitter 15755915008342958081Like on Twitter 15755915008342958082View Tweet 1575591500834295808
Retweet on TwitterVJHemOnc Retweeted
MDAndersonNewsMD Anderson Cancer Center@MDAndersonNews·
13h

At #SOHO22: Our Dr. Robert Orlowski discusses early data in bispecific T cell engagement for treatment of multiple myeloma. @Myeloma_Doc #EndCancer

Reply on Twitter 1575586597206007809Retweet on Twitter 15755865972060078091Like on Twitter 15755865972060078096View Tweet 1575586597206007809
Load More...

IMS 2022

The 19th International Myeloma Society Annual Meeting
25–27 August 2022 | Los Angeles, California
The 19th International Myeloma Society (IMS) Annual Meeting was held in Los Angeles, California, from August 25-27. This meeting brought together leading experts in the field of multiple myeloma to discuss and present preclinical and clinical data, as well as novel approaches in the treatment and diagnosis of myeloma.
View all videos
VJHemOncVJHemOnc@VJHemOnc·
3h

We spoke to @adamssperling (@DanaFarber), who shared some insights into the role of clonal hematopoiesis in multiple myeloma and other hematological malignancies:

🎥: http://ow.ly/GGiK50KVRjM

#MMsm #HemOnc #BloodCancerAwarenessMonth #IMS2022

Reply on Twitter 1575727491070808071Retweet on Twitter 15757274910708080711Like on Twitter 15757274910708080714View Tweet 1575727491070808071
VJHemOncVJHemOnc@VJHemOnc·
12h

We had a great interview with Catherine Coombs of @UNC, who shared some insights into novel BTK inhibitors in CLL and future outlooks.

@SocietyofHemOnc #SOHO22 #HemOnc #LeuSM #CLLsm

Reply on Twitter 1575595071273021442Retweet on Twitter 15755950712730214421Like on Twitter 15755950712730214423View Tweet 1575595071273021442
VJHemOncVJHemOnc@VJHemOnc·
12h

#SOHO22 | Peter Valk (@ErasmusMC) discusses TP53-mutated AML and MDS, the prognostic value of FLT3-ITD residual disease in AML, and more.

Visit http://VJHemOnc.com for our interviews from this year's meeting!

#SOHO2022 #HemOnc #LeuSM #AMLsm #MDSsm

Reply on Twitter 1575591500834295808Retweet on Twitter 15755915008342958081Like on Twitter 15755915008342958082View Tweet 1575591500834295808
Retweet on TwitterVJHemOnc Retweeted
MDAndersonNewsMD Anderson Cancer Center@MDAndersonNews·
13h

At #SOHO22: Our Dr. Robert Orlowski discusses early data in bispecific T cell engagement for treatment of multiple myeloma. @Myeloma_Doc #EndCancer

Reply on Twitter 1575586597206007809Retweet on Twitter 15755865972060078091Like on Twitter 15755865972060078096View Tweet 1575586597206007809
Load More...

Latest videos

View all
1:37
Daratumumab vs isatuximab in the treatment of multiple myeloma
Saad Usmani • 25 Sep 2022
2:41
Identification of myeloma high-risk subclones with single-cell technologies
Jill Corre • 30 Aug 2022
1:16
Perspectives on the role of MRD negativity in multiple myeloma
Saad Usmani • 25 Aug 2022
2:02
The impact of heterogeneity on outcomes in multiple myeloma
Jill Corre • 30 Aug 2022

CAR-T Therapy

View all
2:05
Exciting ongoing trials in frontline transplant-eligible patients with multiple myeloma
Saad Usmani • 25 Aug 2022
3:15
Optimal strategies to manage late-stage multiple myeloma: the promise of anti-BCMA therapies
Salomon Manier • 27 Aug 2022

Antibody-based therapy

View all
2:30
Daratumumab and isatuximab in the treatment of multiple myeloma
Mohamad Mohty • 25 Aug 2022
2:04
Approval of teclistamab in triple-class refractory multiple myeloma
Maria-Victoria Mateos • 26 Aug 2022

MRD

View all
1:16
Perspectives on the role of MRD negativity in multiple myeloma
Saad Usmani • 25 Aug 2022
2:02
The impact of heterogeneity on outcomes in multiple myeloma
Jill Corre • 30 Aug 2022

Trial Updates

View all
2:05
Exciting ongoing trials in frontline transplant-eligible patients with multiple myeloma
Saad Usmani • 25 Aug 2022
2:21
The role of daratumumab in the treatment of myeloma and insights into the MAIA trial
Saad Usmani • 25 Aug 2022

Amyloidosis

View all
1:20
Outcomes of renal transplantation in patients with AL amyloidosis
Nelson Leung • 25 Aug 2022
3:21
Insights into the management of systemic AL amyloidosis
Sandy Wong • 26 Aug 2022

Waldenström’s Macroglobulinemia

View all
1:24
The long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated WM
Steven Treon • 25 Aug 2022
1:30
Bendamustine-rituximab vs ibrutinib as frontline therapy in Waldenström’s macroglobulinemia
Steven Treon • 25 Aug 2022
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals